ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
SiNtx Technologies Inc

SiNtx Technologies Inc (SINT)

3.9701
0.2501
( 6.72% )
Updated: 12:04:04

Empower your portfolio: Real-time discussions and actionable trading ideas.

SINT News

Official News Only

SINT Discussion

View Posts
boston745 boston745 17 minutes ago
β€œEqually exciting, and only achievable because of the material composition and manufacturing process, is that every microsphere in a dose is both radiopaque and radiation-emitting.”
Must be enough Ytirrium to make it radiation emitting. Note that the material composition/process is unique to being able to achieve this. Meaning it'll give them an advantage for this market and its patentable.

I'd thumbs up your post if i could. Apparently i cant on this board only.

Bock, Pezzotti, McEntire, even Ashok were/are all very talented materials engineers based on what i could garner from their work. Even Sonny & his colleague at Missouri S&T are but as more support players (name escapes me atm). Sintx had the talent and it has the material. Why management has failed to do much outside of R&D all these years is all a guess. Seems Sintx is the 80s Chicago Bulls, when they got Jordan/Pippen but didnt win alot, in regards to talent but they lack Phil Jackson as head coach to win a game, lol. Bock and Pezzotti are likely Jordan/Pippen. Based on what ive seen i'd have said Pezzotti is Jordan but his knowledge is broad as far as materials engineering goes. Bock maybe better for Ceramics engineering, idk?

I particularly like this quote from NED med CEO:
You can strategize and plan and execute all you want, but every so often it just comes down to being in the right place at the right time.
Shows a sincerity to his post which is why i posted it in the first place. Dr Bock's reply:

Thank you for your kind words, Richard. I am thrilled to join NED's SAB, and the team at SINTX is beyond excited to continue commercialization of the microsphere technology!
πŸ‘οΈ0
Atlanta1 Atlanta1 1 hour ago
If Michael Jordan has been on the SINTX team since 2008, the coach should have been fired a LONG time ago.....
πŸ‘οΈ0
boston745 boston745 2 hours ago
Richard Yazbeck
President & CEO at NED Medical, Inc. | Interventional Oncology | MedTech
1h

You can strategize and plan and execute all you want, but every so often it just comes down to being in the right place at the right time.

Early in the life of NED Medical, Inc. we had developed our own glass microsphere. But, we realized that ceramic may offer some very unique properties that are especially suited for radioembolic applications. The only problem is that we didn't know who could make it for us the way we had envisioned. Enter SINTX Technologies and the incredible Ryan Bock! Ryan is affectionately known in our household as the "Michael Jordan of Ceramics." We loved working with Ryan so much that we invited him to join our world-class Scientific Advisory Board and executed a collaboration agreement with SINTX for our next phase of work.

I am thrilled with our collaboration with SINTX and I look forward to accelerating our technology towards our clinical trials.
Our successful manufacturing feasibility collaboration with NED Medical demonstrated that SINTX could manufacture novel ceramic-based microspheres containing the Yttrium-90 radioisotope that met NED Medical’s preliminary specifications for a transarterial radioembolization (TARE) device for treatment of hepatocellular carcinoma. Further, these engineered microspheres contain porosity, allowing their future adaptation for targeted chemotherapy and combination therapies,” said Dr. Ryan Bock, CTO of SINTX Technologies.
Understand that Sintx material is the main component of Ned Medical's tech assuming their collaboration is successful. Looks like it has been so far. Obviously i do not know what percent Sintx might see in this product but as its the core product its not going to be small.

Quote Sources:
https://www.linkedin.com/posts/richardyazbeck_sintx-technologies-and-ned-medical-partner-activity-7265371246509408256-mfzP
https://ir.sintx.com/news-events/press-releases/detail/243/sintx-technologies-and-ned-medical-partner-to-advance
πŸ‘οΈ0
boston745 boston745 3 hours ago
Not fluff. Sintx almost always collaborates with small companies like this to de-risk/develop tech before its used for a larger firm. Looks like most of the financial burden will occur on Ned Medicals side while this opens up SIntx to yet another billion dollar market its materials can be used in. I bet there is a large company with eyes on Ned Medical.
The pre-market pump and drop in price is good for longevity of the current bullish trend. It also got us above another resistance point.

amda
12:34 PM
$SINT arubaboy - this was not the PR that some had hoped for. This is the same old SINT fluff bullshit, so some sold the spike out of habit. and shorty jumped on also. But, the reasons for the solid rise recently are still intact, and this dip, imo, is an awesome buying opportunity
The Radiotherapy Market Size was valued at USD 7.01 Billion in 2023 and is expected to reach USD 11.18 Billion by 2032 and grow at a CAGR of 5.54% over the forecast period 2024-2032.”

Quote Sources:
https://stocktwits.com/amda/message/593479713
https://www.globenewswire.com/news-release/2024/09/06/2942153/0/en/Radiotherapy-Market-Size-to-Hit-USD-11-18-Billion-by-2032-Driven-by-Rising-Global-Cancer-Rates-and-Advancements-in-Treatment-Technology-SNS-Insider.html
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 4 hours ago
"There are two disinformation straw puppet accounts mostly trolling me on Sintx and Tesla boards. There's a reason for that: it means what I post is worth deeper examination. More on this later, stay tuned."

A recent development worth noting is the appointment of Mr. HungBum to SintX Technologies. While he was previously associated with HungBum Ventures, a company specializing in electromagnetic shielding undergarments, his new role suggests a potential pivot for SintX towards this promising market.

The global demand for EM shielding solutions, particularly in the context of weakening magnetic fields and solar storms, is substantial, estimated to be worth trillions of dollars. SintX's strategic shift, coupled with the departure of the former CEO, Dr. Sunny Balls, could position the company as a major player in this emerging field.

While some may speculate about potential government involvement, such as the CIA, it's crucial to focus on SintX's core business and its potential to deliver significant value to its shareholders. The company's innovative approach and the expertise of Mr. HungBum could drive substantial growth and make it a pivotal force in the global market."
πŸ‘οΈ0
boston745 boston745 1 day ago
I knew this name sounded familiar. So Mr. Honigblum was a former director and his company Creation Capital was a pre-IPO placement agent/advisor. Looks like Mr Honigblum is rejoining to aid the company again and likely see a nice return.

Includes 50,000 shares that were issued to Mr. Honigblum and 50% of the 12,500 shares that were issued to Creation Capital, LLC (β€œCreation Capital”), of which Mr. Honigblum is a 50% owner. Mr. Honigblum is a managing member of Creation Capital. Mr. Honigblum resigned from our board of directors in September 2013.
Gregg R. Honigblum, the Chief Executive Officer of each of Creation Capital, LLC (β€œCreation Capital”) and Creation Capital Advisors, LLC (β€œCreation Advisors”), joined the Company’s board of directors in December 2006 and resigned in September 2013. The Company completed offerings of preferred stock and convertible debt through Creation Capital, as its placement agent, and it received strategic financial advisory services from Creation Advisors.
Transactions with Creation Capital, LLC and Creation Capital Advisors, LLC

Mr. Gregg R. Honigblum, the Chief Executive Officer and a 50% co-owner of each of Creation Capital and Creation Capital Advisors, LLC, or Creation Advisors, served on our board of directors from 2006 until September 2013. We completed the offering of shares of our Series E convertible preferred stock between March 2010 and July 2010 through Creation Capital, which served as our placement agent. We paid Creation Capital approximately $1,135,000 and issued it a warrant to purchase 567,691 shares of Series E convertible preferred stock at an exercise price of $2.20 per share as commissions.

In connection with the private placement of our Senior Secured Notes between March 2011 and May 2011, Creation Capital served as our placement agent and received $1,049,000 and a warrant exercisable for 57,557 shares of common stock at an exercise price of $56.70 per share as commissions. In February 2012, when we issued an additional $5.0 million Senior Secured Note to Hampshire Med Tech Partners, LP, we paid Creation Capital an additional $212,500.

In June 2012, we entered into a financial advisor consulting agreement with Creation Advisors, pursuant to which we agreed to extend the termination date of the Series C convertible preferred stock warrants previously issued to Creation Capital from February 2013 to February 2018.

In connection with the conversion of our Senior Secured Notes in December 2012, we agreed to pay Creation Advisors a strategic financial advisory fee in the amount of approximately $447,000. We agreed to pay half of the advisory fee, approximately $223,000 in December 2012 and the remaining half within 24 months, which we paid in

I guess i missed this from the press release:

Mr. Honigblum’s deep understanding of the Company’s mission and strategic goals, coupled with his experience as a former member of the board of Amedica, the predecessor of SINTX, positions him to drive the Company’s corporate strategy effectively.

β€œI am honored to join SINTX at this pivotal juncture,” said Gregg R. Honigblum, Chief Strategy Officer. β€œThe Company’s ongoing development of pioneering technologies in the medical device sector positions it at the forefront of commercialization. I look forward to contributing to the team’s efforts in enhancing shareholder value and drive the Company’s vision forward.”

Quote Sources:
https://www.sec.gov/Archives/edgar/data/1269026/000119312514047404/d593074ds1a.htm
https://ir.sintx.com/news-events/press-releases/detail/242/sintx-technologies-appoints-gregg-r-honigblum-as-chief

========================================

amda
11m
$SINT the buyback pretty much elimnates any further dilution, but the money has to come from somewhere. they are debt-free and want to stay that way, so there must be some expectation of strong cash-flow improvment in the not too distant future. this could get VERY interesting....
If Lind exercises it warrants at $50 paying cash, then yes they'll likely not need to do further offerings...at least if i understand things correctly. If not theres always the possibility of cash infusions from one or more of their partners injecting them with capital...but Sintx marketcap must significantly increase before that. Still buying shares at 3 and then doing follow on offering over 50 is a smart move.

https://stocktwits.com/amda/message/593372590

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
πŸ‘οΈ0
boston745 boston745 1 day ago
FNEX capital has alot of money invested in SpaceX. A little invested in Neuralink as well. Even Palantir.

Prior to being appointed as Chief Strategy Officer, from December 2023 to November 2024 Mr. Honigblum served as a Managing Director for FNEX Capital, LLC, a global leader in Private Securities transaction and investment banking.

https://fnex.com/transactions/

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

Theres two disinfo strawpuppet accounts mostly trolling me on Sintx and Tesla boards. Theres a reason for that, Means what i post is worth deeper examination. More on this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175304626


========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 1 day ago
Theyve been doing the hard work and innovating for years. Thats never been the problem. Business strategy, well thats been a bit all over the place and I have my theories on that.

Spill the beans! What's the real deal with SintX technologies? Solar storms, geomagnetic unrest, a weakening magnetic field, family threats, or a divine mission to save humanity from your Mormon hairdresser?

And what about my entertainment future? Where will I go to get my daily dose of wild conspiracy theories and obscure research topics? Let's keep this dead horse kicking for years to come!
πŸ‘οΈ0
boston745 boston745 1 day ago
6 month intervals just like Olsen's original contract. In regards to buying back shares, its not logical for them to buy only $500 worth of shares especially on the day we saw 50m shares trade. My guess is the bulk of that $500k worth of shares was acquired that day. Then they'll release post employee share plan passing news that theyve completed the purchase. I mean thats what id do if I was them.

amda
36m
$SINT
there is so much negative sentiment built in here...upside could be explosive
Need to see gap fill at 13 and i'd love to see the gap fill at the level Noneya suggested months ago.
https://stocktwits.com/amda/message/593329365

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
πŸ‘οΈ0
jimr1717 jimr1717 1 day ago
So they hired a Chief Strategy Officer for a 6 month contract to see if he can get the share price up?
The share buyback? So if they buy $500 bucks of shares back that still falls under the β€œup to $500k”.
πŸ‘οΈ0
boston745 boston745 2 days ago
No need for innovation, hard work, or a solid business strategy.
Theyve been doing the hard work and innovating for years. Thats never been the problem. Business strategy, well thats been a bit all over the place and I have my theories on that. However that "seems" to be back on track for one of Sintx significant partners to step onto stage in the nearish future based on what they are doing and saying. The main issue through the years has been none of their hardwork and innovation has ever impacted the stockprice slowing development. Purposeful or not, thats held the company back. I like the new CSO position which should translate to improved stockprice over time. Improving valuation will do wonders for development and funding trials with partners in addition to finally showing shareholders some sort of return.

β€œGregg’s appointment as Chief Strategy Officer reflects our confidence in his ability to elevate SINTX’s financial and strategic position,” said Eric K. Olson, CEO of SINTX Technologies. β€œHis successful career in emerging technologies and deep investment banking knowledge will be invaluable as we pursue new development opportunities, strengthen investor relationships, and drive our corporate strategy and revenue forward.”

Innovation is why they could participate in all the following markets and even own them through licensing its IP to leading companies in these fields. I'll remove armor market once they actually sell their industrial unit (Aerospace/Defense/Armor). One thing they should look into is water filtration to see if Si3N4 can help purify water in environmental disaster locations. With it being Anti-pathogenic, Si3n4 could be a significant aid to this industry if it works well in that use case. With it being biodegradable it may have diminishing returns for this application. So it depends on how long it performs a certain threshold is my guess.

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Theres two disinfo strawpuppet accounts mostly trolling me on Sintx and Tesla boards. Theres a reason for that, Means what i post is worth deeper examination. More on this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175304626

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 2 days ago
I'd make this a sticky post if i was a mod as its actually informative and not an example of a strawpuppet.

"All Sintx needs is a knight in shining armor, a corporate superhero to swoop in and save the day. A magical partner, a fairy godparent, a white knight on a high horse – whatever you want to call it. If one of their 'significant' partners just steps up to the plate, waves their magic wand, and poof – problem solved. No need for innovation, hard work, or a solid business strategy. Just a little bit of luck and a lot of hope."
πŸ‘οΈ0
boston745 boston745 3 days ago
Its definitely to help increase stock price, signals a change by management (finally), possibly help sell why employee stock plan passes this time when it didnt last year. Regardless, thats not fluff. They have possible cash influxes coming from sell of armor assets and if they sell off their industrial business with other potentials if their partners step up. They cut their burn to about $1-1.5m a quarter so that helps stretch their current cash on hand and makes it easier to get to cash positive with any new medical/Antipathogenic products coming to market. Still they'll look foolish doing this and then raising next year at low prices. I doubt that due to the fact that Lind updated its 13/G, oddly after 9 months, and half its warrants expire in August at $50. Buying back shares appears like maneuvers to bring about 50+ given the timing of all this. Thats only if these various things are all connected.

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
πŸ‘οΈ0
joev2 joev2 3 days ago
Especially since there's no evidence they have the cash. And then what are they going to do...give another 7% to Maxim? I'm guessing it's the usual fluff.
πŸ‘οΈ0
Atlanta1 Atlanta1 3 days ago
have we ever seen a buyback though? this is very strange......
πŸ‘οΈ0
jimr1717 jimr1717 3 days ago
Makes perfect sense for a pump before the next reverse split
πŸ‘οΈ0
boston745 boston745 3 days ago
Forgot to add that Lind's Series F warrants, with there $50 strike price, expire in August. If Sintx purchased most of those shares then 50 is close to $50m valuation not factoring in employee share plan. Keep an eye out from Si3N4/PEEK clearance in 2025.

Each unit was sold at a public offering price of $50.00 resulting in gross proceeds to the Company of $4 million before deducting offering fees and expenses. The Class E and Class F Warrants were immediately exercisable at a price of $50.00 per share. The Class E Warrants expire five years from the date of issuance and the Class F Warrants expire eighteen months from the date of issuance.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224044728/form10-q.htm pg 8
Lind Group's 13G/A
https://www.sec.gov/Archives/edgar/data/1269026/000092963824003929/sch13g.htm

You guys need some Si3N4 implants? Call CTL-Amedica: https://ctlamedica.com/

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
madg madg 3 days ago
Equity raises and then say you're buying 500k of stock back while you generate no income. Incompetence abounds at this company 
πŸ‘οΈ0
Atlanta1 Atlanta1 3 days ago
I hear it's available in Massachusetts.....
πŸ‘οΈ0
jimr1717 jimr1717 3 days ago
Where can this great product be purchased?
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 3 days ago
Sintx Technologies' silicone nitrate has shown to be effective at curing testicular cancer when sprayed on men's nut sacks.

The incidence of testicular cancer is steadily increasing over the past several decades in different developed countries. If on one side better diagnosis and treatment have shone a light on this disease, on the other side, differently from other malignant diseases, few risk factors have been identified. The reasons for the increase in testicular cancer are however unknown while risk factors are still poorly understood. Several studies have suggested that exposure to various factors in adolescence as well as in adulthood could be linked to the development of testicular cancer. Nevertheless, the role of environment, infections, and occupational exposure are undoubtedly associated with an increase or a decrease in this risk. The aim of this narrative review is to summarize the most recent evidence regarding the risk factors associated with testicular cancer, starting from the most commonly evaluated (cryptorchidism, family history, infections) to the newer identified and hypothesized risk factors.
Keywords: testicular cancer, risk factor, genetics, infections, environment, andrology, urology
1. Introduction
Testicular cancer is the most common type of neoplasm among young men aged 15 to 40 years, representing 1% of adult neoplasms and 5% of urological tumors, reaching an incidence of 3–11 cases per 100,000 males per year in the Western world [1]. Although it is relatively rare, testicular cancer is an important public health concern due to its impact on the quality of life and reproductive function of affected men [2]. Early detection and treatment of testicular cancer are crucial to improve outcomes and death risk reduction [3]. In particular, testicular cancer represents a sort of unicity among cancers due to the possibility to be effectively treated with surgery and/or radiation therapy and presenting an overall excellent prognosis, with a >90% cure rate and >95% five-year survival rate, especially for early detected patients [4]. However, considering the lack of clear symptoms and signs in the early stages, with the exception of a unilateral lump or painless swelling, the early detection of the disease could be challenging [5]. This is the reason why understanding the risk factors associated with testicular cancer is crucial for early detection and treatment. The exact causes of testicular cancer are not well understood, but several risk factors have been identified, including age, cryptorchidism, abnormal testicle development, personal and familiar history of testicular cancer, ethnicity, and a weakened immune system [6]. Additionally, certain medical conditions, such as Klinefelter syndrome and Down syndrome, may also increase the risk of developing testicular cancer [7,8,9]. Considering the rarity of the condition, the relative ease of diagnosis due to the accessibility of the testis to imaging and clinical exploration, and the potential impairment to fertility related to the treatment, the role and the identification of risk factors in the development of testicular cancer still represent a topic of high clinical interest. The aim of this research paper is, therefore, to examine and summarize the current state of knowledge regarding the risk factors for this malignancy, including demographic and environmental factors, lifestyle factors, and medical conditions, posing particular attention to the most recent evidence and hypotheses.
2. Epidemiology and Global Trends
Although testicular cancer represents a relatively rare disease, accounting for about 1% of cancers and ranking 26th for cancer incidence in men, the estimated overall incidence worldwide in 2020 was 74,458 cases with an age-standardized rate of 1.8:100,000 among all cancers, showing an increase of over 1.80-fold in the last 25 years [10]. In particular, when geographical areas are considered, Asia, Europe, and Northern America reported the highest estimated incidence rate with, respectively, 5,021,195, 2,339,617, and 1,372,002 cases, for an ASR of 185.2, 328.5, and 397.9:100,000. Regarding mortality, testicular cancer reported a total of 9334 estimated deaths worldwide, with an ASR of 0.22:100,000, mostly distributed among Asia (3997 deaths, ASR 0.16:100,000), Latin America (2139 deaths, ASR 0.60:100,000), and Europe (1568 deaths, ASR 0.34:100,000) [11,12]. The global pattern of testicular cancer incidence and mortality is however highly heterogeneous, with a higher incidence rate in high human development index (HDI) countries and, conversely, a higher mortality in low HDI countries. This data is consistent with adequate diagnosis and treatment protocols implemented in the highest-income countries since the 1970s, associated with reduced exposures to well-known risk factors such as cryptorchidism and pharmaceuticals during pregnancy [13,14]. Conversely, in lower HDI countries such as Latin America, testicular cancer mortality rates have increased in parallel to incidence due to inequitable distribution of specialists and centers and difficulties in accessing cancer care for rural and remote populations [15,16].
3. Etiology and Histopathology
Testicular cancer could derive from any cell type found in the testicles. Nevertheless, more than 95% of testicular cancers arise from germ cells, which are further divided, according to the histologic features, into seminomas, non-seminomas, and spermatocytic seminomas. The remaining 5% is represented by sex cord or stromal cell tumors as well as miscellaneous non-specific stromal cell tumors [17]. Interestingly, the incidence of testicular cancer does not increase with age but instead presents a peak at 25–29 years for non-seminomas and 35–39 for seminomas [18,19]. Despite several environmental and hormonal factors that have been hypothesized to be related to testis carcinogenesis, nevertheless, the only factors clearly associated with testicular cancer are prior unilateral testicular cancer, family history of testicular cancer, and congenital anomalies such as cryptorchidism [20,21,22]. Germ cell tumors develop secondary to a tumorigenic event in utero, successively leading to an intratubular germ cell neoplasia, which is derived from gonocytes that failed to differentiate into spermatogonia. With the hormonal changes happening during puberty, these cells develop their invasive potential. Seminomas consist instead of transformed germ cells with a blocked differentiation. Finally, embryonal carcinoma cells are more similar to undifferentiated stem cells with a gene expression similar to those cells and intratubular germ cell malignancies. Stromal cell tumors, as well as sex cord and non-specific stromal tumors, have instead an extraembryonic/somatic differentiation [18,23].
Testicular cancer definitions are based on cell type derivation. According to the WHO, the histopathological classification comprises [24]:
Germ cell tumors.
Derived from Germ Cell neoplasia in situ (GCNIS): seminoma, embryonal carcinoma, yolk sac tumor (post-pubertal), trophoblastic tumors, teratoma, mixed germ cell tumors.
Germ cell tumors unrelated to GCNIS: spermatocytic tumor, yolk sac tumor (pre-pubertal), mixed germ cell tumor (pre-pubertal).
Sex cord/stromal: Leydig cell tumor, Sertoli cell tumor, granulosa cell tumor, thecoma, unclassified, gonadoblastoma.
Miscellaneous non-specific tumors: ovarian epithelial tumors, tumors of the collecting ducts and rete testis, adenoma, carcinoma, adenomatoid tumor, mesothelioma, epididymal tumor, cystadenoma of the epididymis, papillary cystadenoma, mesenchymal tumor of the spermatic cord.
4. Epidemiological Risk Factors
4.1. Cryptorchidism
Cryptorchidism is the most common birth defect involving male genitalia and is characterized by the absence of at least one testicle from the scrotum, most commonly the right. Up to 80% of cryptorchid testes descend within the third month of life [25]. Nevertheless, about 10% of all cases of germ cell tumors occur in men with a history of cryptorchidism with the most accredited hypothesis related to the elevated temperature of the undescended testis, thus inhibiting the differentiation of spermatogonia and resulting in an arrest of spermatogenesis, germ cell depletion, and fibrosis. In addition, the altered position of the testis could alter the function of the somatic cells forming the niche for spermatogonial stem cells’ self-renewal and differentiation. The overall risk of developing testicular cancer in patients who were or are cryptorchid is 3.7–7.5 times higher than in the normal population [26,27]. Although corrective surgery diminishes this risk by half, the former cryptorchid testis becoming cancerous indicates that permanent epigenetic changes are reported in the testis [28]. Recent evidence suggests that allelic variants in genes implicated in the development of the testes could be present in a patient with cryptorchidism. In particular, KIT gene variants might be the determinants in the association between this condition and testicular cancer [29]. However, up to now, even if an irrefutable higher risk of testicular cancer in patients affected by previous or current cryptorchidism has been found, the real pathogenetic mechanism underlying this association is still unclear [30].
4.2. Family History
Based on clinical observations and systematic investigations, it has been suggested that a family history of testicular cancer represents a major risk factor for this kind of cancer. In particular, it has been evaluated that there is a 3.1-fold increased relative risk for first-degree relatives of patients with testicular cancer, despite the fact that the age at presentation was not significantly different compared to patients without a familiar history of this cancer [31]. A proper familiar testicular cancer, i.e., two or more affected men in the same bloodline, is quite uncommon, although it has been estimated to occur in about 3% of families. Nevertheless, considering the rarity of the condition at the baseline, a genetic analysis is difficult and even when it has been performed, no cytogenetic abnormalities were found [32,33,34]. A prospective study involving about two million males born from 1951 to 2015 reported 2686 cases, highlighting a 6.3-fold risk for brothers of patients affected by testicular cancer, 4.7-fold for sons, 4.4-fold for fathers, 2.0-fold for paternal uncles, and 1.9-fold for maternal uncles. Interestingly, an increased risk for testicular cancer was found also for patients with a family history of mesothelioma (4.4 to 2.8-fold), malignant melanoma (1.4-fold), and malignant neuroepithelial tumors (11.1 to 4.6-fold), suggesting, in those cases, the existence of hereditary cancer syndromes [35]. Several other previous linkage studies reported similar conclusions, adding interesting data such as a higher prevalence of cryptorchidism and a younger age at diagnosis among cousins pairs; a similar age of testicular cancer development among relatives; a potential role of shared childhood environment [36,37,38].
4.3. Maternal and Perinatal Factors
Considering the natural history of testicular cancer and the relatively young age at the diagnosis, exposure to risk factors during early life could be a part of the initial stages of carcinogenic transformation. Cryptorchidism represents the most obvious example. In particular, a recent meta-analysis suggested how low birth weight, perinatal inguinal hernia, and twinning, in addition to cryptorchidism, are associated with an increased risk of testicular cancer, reporting, respectively, an odds ratio (OR) of 1.34, 1.63, and 1.22 [39]. Another potential risk factor is associated with the age of the mother at conception. In particular, older ages of mothers at conception were associated with a reduced risk of testicular cancer (OR = 0.73), in addition to a relatively lower risk in men who had been breastfed for 6 months or more (OR = 0.63) [40]. These findings support the potential role of higher estrogen exposure in mothers as a potential risk factor for testicular cancer [41]. Interestingly, to support this evidence, a comprehensive meta-analysis by Hom et al. reported an overall OR = 2.98 for testicular cancer in mothers who were exposed to synthetic estrogen diethylstilbestrol (DES) during pregnancy [42]. Although DES use had been stopped in 1971, it is widely suspected that exposure to other endocrine-disrupting chemicals with estrogenic activity has a role in the carcinogenesis of testes [43].
4.4. Age
As previously reported in the epidemiological data, the age distribution of testicular cancer presents a peak at the ages of 25–35 while a smaller peak is reported after 80 years of age. The peculiar age distribution of this cancer is mostly supposedly related to sex hormone activity. Nevertheless, testicular cancer is rare before age 15 [44]. Regarding testicular cancer in older men (>50 years), it has to be reported, however, that the most commonly occurring testicular malignancy is testicular lymphoma, often secondary to non-Hodgkin lymphoma, while the primary testicular lymphoma is rare and could have a different age range [45,46,47].
4.5. Ethnicity
Different research posed particular attention to the ethnic differences in testicular cancer, considering that the incidence of this disease largely varies among Caucasians, Hispanics, Asians, and African-Americans. In particular, as reported by Li et al., which analyzed the data of SEER (Surveillance, Epidemiology and End Results), Caucasians reported the highest incidence rate (2.08:100,000), followed by Hispanics (1.19:100,000), Asians (0.60:100,000), and African-Americans (0.36:100,000) [48]. Nevertheless, considering the increasing incidence in the last years also in Hispanics (+2.10% yearly) and Asians (+2.47% yearly), it could be highly possible that environmental exposures or socio-economical disparities could interact synergically with genetic susceptibility [49,50].
4.6. Hormonal Levels
Apart from the role of hormones during fetal life, little to no evidence is reported regarding the effects of sex hormones on testicular cancer. A 1997 study by Petridou et al., reported how patients with baldness reported a lower risk of testicular cancer, suggesting indirect evidence of the protective role of androgens regarding testicular cancer [51]. In particular, to support this hypothesis, a previous study by Depue et al. showed how a story of severe acne at puberty was inversely correlated with testicular cancer. Despite the likely relation of androgens to pubertal acne, it has not been conclusively established [52,53]. A more recent meta-analysis by Zhou et al. reported a protective role of baldness against testicular cancer, with an OR = 0.61, however, the work was performed on five case-control studies, thus limiting the potential conclusions [54]. Finally, a study by Nakagawa et al. showed a protective role of the androgen pathway on testicular cancer, suppressing the cell growth of seminomas in vitro and in vivo [55].
4.7. Age at Puberty
Several studies have reported a potential link between early puberty and increased risk of testicular cancer, although data are controversial [56]. It is known that patients with precocious puberty are at increased risk of Leydig cell tumors, a rare testicular tumor that could provoke a pseudo precocious puberty [57]. A meta-analysis by Maule et al. involving 12 studies showed a protective role of late puberty (defined as the age of starting shaving), reporting an OR = 0.87 with no effects of early puberty on testicular cancer risk [58].
4.8. Body Mass Index
The association between body mass index (BMI) and testicular cancer is also controversial. Although height has been somewhat associated with an increased risk of germ cell testicular cancer in a 2002 study, no significant associations were found regarding BMI and weight. As stated by the authors, this data could be a proxy for energy intake during early life and therefore could be biased [59]. Conversely, a 2006 study by Bjørge et al. reported, on 1357 testicular cancers, a protective role of increased BMI, with overweight and obese men showing an OR of 0.89 and 0.83, respectively. Interestingly, the risk of testicular cancer was not associated with adolescent BMI [60]. Another study by Dieckmann et al. reported, instead, on a total of 8498 testicular germ cell cancer patients, an increased risk for testicular germ cell cancer in young patients with BMI 25 to <30 kg/m2 [61]. Finally, a meta-analysis by Lerro et al. reported, on a total of 14 studies, an increased risk of testicular cancer for every 5 cm of height (OR = 1.13), along with a protective role of weight (OR = 0.92), providing support for a positive association between height and testicular cancer and a hypothetical protective role of increased BMI versus this cancer [62].
4.9. Infections
The relation between infections and testicular cancer relies mostly on the response to chronic inflammation which is involved in several different steps leading to carcinogenesis. Inflammation cells such as macrophages and leukocytes produce, indeed, reactive oxygen and nitrogen species that could affect DNA integrity [63,64]. One of the first infections identified as a possible risk factor for testicular cancer is represented by HPV, as reported by Garolla et al. In particular, analyzing 155 testicular cancer patients, the prevalence of HPV infection in the semen was 9.5% compared to 2.4% in healthy controls [65]. A large meta-analysis by Trabert et al., involving a total of 767 patients with 929 healthy controls, reported, instead, in an evaluation of different childhood infections as mumps and orchitis, the absence of a certain association between these infections and testicular cancer [66]. Another contemporary meta-analysis by Yousif et al. analyzing EBV, CMV, Parvovirus B19, and HIV, reported an OR for testicular cancer of, respectively, 4.80, 1.85, 2.86, and 1.79, supporting a possible association between these infections and testicular cancer. However, the marked heterogeneity of the studies involved and the relatively small sample size led the authors to consider this association with a certain caution [67]. Interestingly, Kao et al. reported, in patients with a prior diagnosis of epididymoorchitis, a higher prevalence of testicular cancer compared to those without a history of this disease (11% versus 0.3%), with an impressive OR, calculated via a conditional logistic regression analysis, of 38.24 which increased to 47.17 when adjusted for other variables (urbanization level, presence of testicular microlithiasis, and geographical region), highlighting an important role of epididymoorchitis in testicular carcinogenesis. Unfortunately, the limited geographical area (China), the lack of information regarding bacterial culture, and the impossibility to exclude other risk factors such as family history and occupational exposure, limit the results obtained in this study [68]. Finally, a newer and more recent meta-analysis from Garolla et al. reported, on a total of 20 studies with 265,057 patients included, an association between EBV and HIV to testicular cancer, with an OR of, respectively, 7.38 and 1.71 while no association was instead found for HPV, CMV, and Parvovirus B19 [69].
4.10. Testicular Trauma
Testicular trauma has been included in the past as a potential risk factor for testicular cancer but its current role in testes carcinogenesis has been diminished [70]. Despite an initial elevated risk for testicular cancer in relation to the testis or groin trauma having been found, data were inconsistent and the hypothesis of an aetiologic role of testis trauma in testicular cancer has not been supported [71]. It seems more plausible that a prior testis trauma could lead the patients to seek proper medical attention and, therefore, lead to the diagnosis of testicular cancer [72,73].
4.11. Smoking
Testicular cancer appears to have the least amount of data related to its relationship to cigarette and tobacco smoking. According to a study by Srivastava and Kreiger, a significant association was found between testicular cancer and smoking, in particular for those who smoked 12 to 24 pack-years, reporting an OR of 1.96 which could increase up to 2.31 [74]. Nevertheless, a recent meta-analysis found only a slight relevant association between these two factors, reporting an OR of 1.18 [75]. Even if this association was not fully confirmed, interesting data was found in the study by O’Donnell et al. which reported, in men already diagnosed with testicular cancer, an increased OR of 1.86 of having a large tumor >4 cm in smokers compared to nonsmokers with a significantly increased risk of relapse after therapy (OR = 2.05) [76]. Data regarding passive smoke or during pregnancy yielded controversial results, with no clear association found between the exposure to smoke in utero and the development of testicular cancer [77,78,79].
4.12. Drugs
Differently from the exposure to tobacco smoke, the use of recreational drugs and, in particular cannabis, seems to be associated with an increased risk of testicular tumor. Compared to a never-user, the consumption of cannabis yields a twofold increase in developing testicular cancer, with an OR of 1.94 while the use of cocaine was negatively associated with this tumor (OR = 0.54) [80]. A meta-analysis involving three studies highlighted how the current, chronic, and frequent cannabis use was strongly associated with the development of testicular germ cell tumors, reporting an overall OR of 2.49 while no evidence was found regarding the association with seminoma tumors [81]. The rationale underlying this association is, however, still unclear.
4.13. Physical Activity
The role of physical activity in testicular cancer represents another controversial factor. As reported by an old study, strenuous physical activity was associated with a moderate effect on the risk of testicular cancer, reporting an OR = 2.36 which increased to 2.58 for strenuous physical activity greater than five times a week [82]. Nevertheless, more recent evidence reported no association with testicular cancer, with a lack of internal consistency of the findings of prior studies [83,84]. As for other risk factors, a meta-analysis including thirteen studies permitted to clear the contrasting findings, reporting, indeed, no evidence of an association between physical activity and subsequent risk of testicular cancer. However, it has to be stated that the observational studies included in the meta-analysis had several limitations which could have affected the results and the heterogeneity of the findings. This lack of association should, indeed, not be interpreted as the non-existence of potential effects of physical activity on testicular cancer risk and further studies should be required [85].
4.14. Diet
Diet has been associated with testicular cancer in several older studies, with particular attention to the consumption of milk and dairy products. In a study crossing the data of the International Agency for Research on Cancer (IARC) and the Food and Agriculture Organization (FAO) on 42 countries, cheese was most correlated with the incidence of testicular cancer between 20 and 39 years, followed by animal fats and milk, reporting a correlation coefficient (r) of 0.804 when consumed at prepubertal ages and 0.654 when consumed after puberty [86]. In an effort to evaluate this correlation between dairy products and animal fats and testicular cancer, Walcott et al. conducted a hospital-based case-control study involving 159 patients and 136 matched controls, in order to explore, considering the potential influence of estrogens in testicular cancer, the relationship between dietary phytoestrogens and testicular cancer. Although a U-shaped pattern was observed for coumestrol (a natural organic compound acting as a phytoestrogen) and lignans (a large group of polyphenols found in plants), no consistent data was observed [87]. Bonner et al., in a similar study pattern involving 117 patients and 334 controls, did not report any correlation between diet and testicular cancer, although a significant protective role of vitamin E was reported (OR = 0.51) [88]. Conversely, Garner et al. reported, in a case-control study involving 601 patients and 744 controls, a significantly increased risk of developing testicular cancer in subjects consuming high levels of dairy products (OR = 1.87), red meat (OR = 1.49), and baked products (OR = 1.47) [89]. Similar results were reported in two more recent studies, with adjusted OR of 2.37–2.55 for high consumption of dairy products [90,91].
4.15. Heat
The role of testicular temperature and heat in testicular function is well known since the 1960s [92,93]. Starting from this evidence, researchers have investigated the possible association between increased testicular temperature and testicular carcinogenesis. To date, no relationship between these conditions has been found despite a potential role of extreme temperatures in the workplace leading to the hypothesis of a potential association with testicular cancer [94]. Similarly, no association was found between varicocele and testicular cancer [95].
4.16. Electromagnetic Fields
The effects of electromagnetic fields on testicular cancer, similar to other minor risk factors, are controversial. If 1990s studies reported a potential increased risk of testicular cancer for subjects professionally exposed to a magnetic field, more recent studies did not report an increased risk of testicular cancer even in subjects working near radar units, radiofrequency emitters, electrical machines, and high-voltage lines [96,97,98,99]. Nevertheless, sporadic case reports and small series have reported cases of testicular cancer in workers exposed to radiofrequency waves [100,101]. Similarly, regarding the use of cellular and cordless telephones, no increased risk of testicular cancer was reported [102].
4.17. Occupational Risk Factors
Several occupational studies have investigated potential occupations with increased risk of testicular cancer, highlighting how some occupational exposure could also involve higher exposure to environmental factors for occupational purposes [103]. Plastic-related industries were initially associated with an increased risk for testicular cancer, particularly for those involving the production and manufacturing of polyvinyl chloride (PVC). Nevertheless, although a potential link with PVC was suggested due to the exposure to xenoestrogens–phthalates used in PVC which have estrogenic properties, no association was found [104,105]. Similarly, no association was found for other plastic components such as styrene and urethane [106]. Workers in metalworking industries, notwithstanding a heterogeneous range of occupations which makes it difficult to compare cohorts, reported an increased risk for testicular cancer among furnace workers (standardized incidence ratio [SIR] = 2.30), metal temperers (SIR = 5.85), watchmakers (SIR = 7.52), and precision toolmakers (SIR = 2.15) [107,108]. Similarly, paper workers reported an increased risk for testicular cancer (SIR = 7.4) [109]. Nevertheless, it could be possible that considering the high heterogeneity of workers, the retrospective nature of the studies and the presence of potential confounding factors (such as socio-economic status), the data obtained would be highly biased, albeit the effects of heavy metals and extreme temperatures are well known to alter the functionality of testis [110,111,112].
Among concrete workers, which report an overall increased risk of malignant neoplasm, no evidence was found regarding a potential increased incidence of testicular cancer while a study by Dement et al. reported an increased rate of testicular cancer in carpenters (SIR = 2.48) [113,114]. No association with testicular cancer was instead reported for woodworkers and painters [106,115].
Regarding public safety workers, firefighters reported an increased risk of testicular cancer in two studies, with, respectively, a SIR = 3 in the study by Bates et al. and OR = 4.3 in the study by Stang et al. [116,117]. A more recent meta-analysis by Laroche et al. reported an increased risk of testicular cancer in firefighters with an OR ranging from 1.34 to 2.02 [118]. The possible rationale, even if still unclear, could be related to the exposition of chemical compounds that could act as endocrine-disrupting factors [119]. For what concerns police officers, a positive association was found with testicular cancer (OR = 1.31) which was mostly attributed to hand-held radar [108]. However, in a recent study by Sritharan et al. involving 22,595 police officers, this association was not confirmed as statistically significant [120]. Finally, regarding the investigated risk of testicular cancer in military and related personnel, results were controversial. If, on one side, data revealed a comparable rate of testis malignancy between the military and general population, on the other side, the cases expected in military personnel deployed in the Balkans during 1989–99, as well as the Gulf War, were increased about fourfold [108,121,122,123]. However, it could be possible that an active military lifestyle including operational temporary and long-term deployments could contribute to delayed diagnosis and subsequent treatment, potentially biasing data [124].
Despite a lower prevalence of overall cancer incidence among farmers, pesticides are associated with an increased risk of testicular cancer up to threefold, with a significant exposure-response trend [125,126,127]. In particular, exposure to organochlorine pesticides is associated with an increased risk of testicular cancer (OR = 3.01–3.23) [90]. A more recent study by Lerro et al. re-evaluated this risk, reporting an OR of 1.31 [128]. The rationale underlying the association between pesticides and testicular cancer is related to the endocrine-disrupting activity of these compounds which could influence the risk of testicular cancer both during prenatal and postnatal life [129].
Finally, the relationship between occupational and medical exposure to ionizing radiation and testicular cancer has been denied by a systematic literature review performed by Yousif et al. [67].
5. Genetic Risk Factors
Despite the lack of clear evidence supporting the genetic background of testicular cancer and the importance of environmental factors in contributing to the development of testicular cancer, the important and crucial role of genetics in the development and risk of testicular cancer is undeniable. Unfortunately, the lack of reliable studies, mostly limited by the rarity of the condition and, therefore, the difficulty in reaching a large sample size, represent one of the major challenges in unveiling the role of genetics in this disease. Starting from linkage studies, such as that of Crockford et al. which involved 237 pedigreed families with a history of testicular cancer, or that of Nathanson et al. which identified the chromosome Y AZFc region (with a gr/gr deletion) as a testicular cancer risk locus, yielding an OR of 3.2 and 2.1 in familial and sporadic testicular cancers respectively, six regions of interest on chromosomes 2p23, 3p12, 3q26, 12p13-q21, 18q21-q23, and Xq27 were identified as susceptibility loci [33,130]. Other gene mutations associated with testicular cancer are those related to KRAS and KIT. The first encodes a GTPase that activates, among its downstream target, the MAPK and PI3K-AKT pathways. The hyperactivations of these pathways are however associated with the initiation of tumorigenesis in many cancers [131,132]. The second encodes a tyrosine kinase transmembrane receptor and its mutations are observed in up to 25% of seminoma cases [133]. Differently from other malignancies, testicular cancer is, however, a genetically complex and polygenic disease and multiple risk loci contribute to the testis carcinogenesis [134,135]. Three genome-wide association studies have reported several cancer-risk alleles associated with single nucleotide polymorphism. Rapley et al., Turnbull et al. and Kanetsky et al. revealed other loci associated with testicular cancer related to single nucleotide polymorphism changes affecting KITLG (ligand for the tyrosine kinase KIT; OR = 2.69), SPRY4 (inhibitor of mitogen-activated protein kinase downstream of KITLG-KIT; OR = 1.37), BAK1 (similarly to the previous one; OR = 1.50), DMRT1 (involved in gender determination; OR = 1.37), and TERT and ATF7IP (involved in telomere maintenance; OR = 1.54 and OR = 1.27, respectively) [136,137,138]. More recently, the number of interested loci has reached the number of 44, further highlighting the heterogenic and polygenic characteristics of testicular cancer [139]. Overall, three possible pathogenic mechanisms have been hypothesized starting from the identification of these involved loci. The first one is related to the risk loci associated with the transcriptional regulation of cell development (i.e., GATA4 and GATA1), in particular those involved in the specification and differentiation of postnatal testicular development [140,141,142]. The second one involves the genes PRDM14, SALL4, POU5F1, and DMRT1 which are related to the germ cell specification, sex determination, and maintenance of pluripotency of embryonic stem cells [137,143,144,145,146]. The third one, lastly, is associated with genes involved in microtubule and chromosomal assemblies such as TEX14, WDR73, PMF1, CENPE, and PCNT [139,143,147,148,149].
6. Testicular Cancer: A Multifactorial Disease
As for other malignancies, testicular cancer represents a particular example of the interaction between genetic and environmental factors. Despite an undeniable genetic predisposition, this disease heavily reflects the exposure to certain environmental factors and occupational exposures (Table 1 and Table 2). Indeed, both infertility and testicular cancer share a common origin during fetal life, with a potential noxa that impairs the function of Sertoli and Leydig cells, altering the proper testis function, from germ line development to hormone production. This condition, which could be associated with hypospadias and cryptorchidism, is commonly defined as testicular dysgenesis syndrome (TDS) and represents one of the models that permit the description of the pathogenesis of testicular cancer, being associated with this malignancy in over 25% of cases [150,151]. TDS is undoubtedly a multifactorial disease with established causes of severe forms being primarily genetic (i.e., SRY mutation, androgen insensitivity). Nevertheless, the significant increase in testicular cancer in the last years cannot be explained by genetic factors alone and environmental and lifestyle factors have to be considered both for testicular cancer and TDS [152,153]. Furthermore, due to the consideration of the relation between age, androgens, and testicular cancer, the presence of hormonal alterations as well exposure to endocrine-disrupting compounds could represent, in addition to hereditary predisposition and in utero alterations, another side of the coin, due to the potential second hit on testis carcinogenesis processes [129].
Table 1.
Known risk factors associated with testicular cancer.
Known Risk Factors OR Reference
Cryptorchidism 3.7–7.5 [26,27]
First-degree relatives of patients with testicular cancer 3.1 [31]
Brother with testicular cancer 6.3 [35]
Father with testicular cancer 4.4 [35]
Low birth weight 1.34 [39]
Exposition to diethylstilbelstrol during pregnancy 2.98 [42]
Height (every 5 cm increase) 1.13 [62]
Open in a new tab
Table 2.
Probable risk factors associated with testicular cancer.
Risk Factor Limitations Reference
Caucasian ethnicity Socio-economic and environmental exposure disparities [49,50]
HPV, HIV Marked heterogeneity [67]
Epididymoorchitis Limited geographical area of the study, lack of bacterial culture and data regarding environmental exposure [68]
Smoking Several confounding factors [75,76]
Cannabis use Rationale still unclear [80,81]
High consumption of dairy products, red meat and baked products Limited reliability of data acquired via questionnaires [89,90,91]
Exposition to electromagnetic fields Few studies, case reports [100,101]
Occupational exposure to plastics and high temperatures High heterogeneity, biased data [104,105,106,107,108]
Occupation as firefighter and military personnel Hypothesized exposition to endocrine disrupting factors [108,117,118,121,122,123]
Open in a new tab
7. Conclusions and Future Perspectives
Current information on the causes of testicular cancer as well as risk factors for this disease is still limited, and even if the aim of this review was to summarize global data on testicular risk factors, most of the available data are geographically limited to the United States and Northern Europe, especially when considering occupational risk factors. Although a large piece of knowledge suggests that most testicular cancers originate from a potential noxa during fetal life, the role of the environment, familial history, ethnicity as well as diet and occupational exposures are a few of the actors involved in testis carcinogenesis. The relative rarity of the condition has limited the possibility to perform large linkage studies as well as investigate several modifiable factors such as drugs and diet [89,154]. Considering that testicular cancer is one of the most curable types of cancer and the high survival rate, improvement in the early diagnosis could further limit the impact on the health and fertility of this disease. Despite the increasing technological advancement in diagnostic tools and techniques, with the consolidation of the role of liquid biopsy and imaging in most urological cancers including testicular cancer, the identification of risk factors associated with testis carcinogenesis could further improve the chance of proper treatment and early diagnosis, permitting to intercept possible populations or individuals at risk, tailoring appropriate screening and surveillance measures [155,156,157,158]. Currently, the main limitation to the identification of probable and unknown risk factors related to testicular cancer is related to the relative rarity of the conditions which could have not permitted the enrollment of large cohorts for epidemiologic and linkage studies. Similarly, the studies analyzing the genetic risk factors suffer from the same limitations, due to the difficulties in obtaining sufficient data regarding the lineage of families affected by this disease. However, the possibility to organize countries and even continent-related studies could provide further insight into the epidemiologic risk factors linked to testicular cancer. Nevertheless, while the identification of these risk factors would be pivotal in further understanding the disease, several limitations have to be reported. Firstly, some risk factors traditionally associated with testicular cancer are still not well understood in terms of pathogenesis (i.e., cryptorchidism and age), making it difficult to accurately quantify their impact on the development of the disease. Additionally, other risk factors may be influenced by confounding variables, making it challenging to determine their true relationship with testicular cancer (i.e., familial history, age at puberty, infections). Another limitation is instead related to the fact that not all individuals with known risk factors for testicular cancer will actually develop the disease, highlighting the need for further research aimed at assessing the underlying mechanism which contributes to testis carcinogenesis. Lastly, the identification of risk factors alone could not predict high-risk individuals as many cases occur in individuals with no known risk factors [159,160]. A comprehensive approach that takes into account both epidemiologic and genetic risk factors is necessary to accurately assess individual risks of developing testicular cancer and, therefore, tailoring a proper screening.
πŸ‘οΈ0
jimr1717 jimr1717 3 days ago
Don’t forget to sell the pop. This pos will be right back where it was
πŸ‘οΈ0
joev2 joev2 3 days ago
Agree. Big word in there though...... "If"
They could easily buyback $500k worth of stock right now if they knew revenue was going to increase enough,....
πŸ‘οΈ0
boston745 boston745 3 days ago
No, what i want to hear is one of their large partners stepping up and taking a stake in Sintx. This move could be done to help increase Sintx value for that eventuality or it could be something else. They could easily buyback $500k worth of stock right now if they knew revenue was going to increase enough, expected to sell Sintx Armor machinery (which could inject them millions in cash), or are actually going to divest industrial to say NP. This could also being done to help handle votes next year. They are essentially removing up to 20% of the float which they will issue out to employees thus giving employees a larger stake in the company. They could become very wealthy doing this and then Zimmer Biomet steps up finally. Although Madg thinks Solventum (3M) is superior.

We believe that the current market undervalues SINTX’s potential,” said Eric Olson, CEO of SINTX Technologies.
Ya, this has been true for years! Nice if they are finally doing something about it.

Recall Lind Capital, one of Ansons family of funds, just updated their warrant holdings. The strike price of which should be at $50. This will help aid the stock getting there so they can convert and increase their percent of the company.

========================================

Here is a collection of my research going over multiple subjects pertaining to Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other reseearch topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175270333

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
joev2 joev2 3 days ago
What? The stock is up over 50% on 11 million shares already pre-market???? What news could it be? Oh, hmm a maybe purchase of up to $500000 in a share buyback (none of which has to occur). And.....they're using Maxim to help them along? Regardless, I'm sure Boston will be happy, seeing Sint is saying what he wants to hear. Since there is nothing in the works that appears to show nice income coming along, I expect (as always) this to fade and IF Sint is dumb enough to repurchase, they too will feel a bit of what retail has been feeling all along. Go get 'em Sint!
πŸ‘οΈ0
jimr1717 jimr1717 4 days ago
Oh that’s just wonderful. 8 years later and Zip β€œ product to market”.
Will it be 10 years, 15, 18 until everyone figures out this blatant sham?
It didn’t take me more than an hour of DD.

BTW the automobile has maime and killed since the day they were built.
Should we go back to the horse and buggy?

Only the Fools are Fooled.
πŸ‘οΈ0
boston745 boston745 4 days ago
Tesla is a fake it until it makes it scam that is being pumped to help fund SpaceX tender offer just like it did back in June. Sintx is not a scam. Real products real partners. Just a matter of getting products to market. Significant potential that can save lives while Tesla continues to maime and kill while it pretends its product is safer than it is.

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439

Evidence suggesting Sintx and NP Aerospace are working on female specific armor
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175356997


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
jimr1717 jimr1717 4 days ago
A β€œscam” is a scam is a scam. Why no links to all of the wonderful DD that you have presented in the past.

Only Fools are Fooled.
πŸ‘οΈ0
boston745 boston745 4 days ago
The scam here is to make others think this is a scam so either management can sell the company cheap, or merge with NP Aerospace, or some other entity could try to acquire the company cheap. All depends on if Anson family of hedge funds is working with or against Managements intentions.

The fact that Sabby played the pump in 2020 and management acquired executive liability insurance suggests collusion on their part and that management is preparing for lawsuits when they say reverse merge with NP Aerospace for cheap or some other variation. I hope the recent update means they cancelled that plan. We shall see.

πŸ‘οΈ0
joev2 joev2 4 days ago
Bravo! Apparently there is the gift of telepathy among the many that self-absorbed individuals think they possess. As far as the con bit, I'm not the one recommending and defending this piece of crap over all these years. What's the stock value from the day you began posting? I think it will be quite easy and clear for everyone to see who and what the real con is here. And...they don't even need a special gift of some sorts to figure it all out.
Post is styled to an emotional appeal to generate outrage in the reader. All the components of a con
Btw, no need to waste one of your precious few posts for the day on a reply. I already know the game. When you speak, it's fact. When others speak in a contrary way, it's too elicit an emotional response but isn't factual. The only problem of course is the FACT that every fact YOU post, the stock goes in opposite direction, corresponding to the emotional appeal of the naysayer (stock also going down). Absolutely hilarious. Imagine if Wall Street really operated this way? By golly, Sint would be worth what Tesla is with Tesla doing a Sint. I can see it now. There goes Sonny being part of the transitional team for the new guy in office. Lol...
πŸ‘οΈ0
jimr1717 jimr1717 4 days ago
This is a solid investment. Most would find that its avalanche chart is second to none.

The depreciating asset investment here has to be close to the top in the market.
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 4 days ago
Who cares about management when we're sitting on a gold mine of internal wealth! Remember, folks, the IP is worth billions, even if the entire company can be purchased for a few million. Whoever buys them out at bankruptcy will hit the jackpot.

If they can capture just 5% of the fictional applications I've outlined, we'll generate over $800 billion in annual revenue and compete with giants like Apple and Tesla. People know who I am, and influential insiders are reading my every post.

My Thai ladyboy wife and special needs son has faced death threats, and I've even been targeted at work and have already received an atomic wedge. But I won't stop defending the groundbreaking silicone nitrate technology of SintX, which is unmatched worldwide
πŸ‘οΈ0
jimr1717 jimr1717 5 days ago
β€œ I dont really care about management”
Perfect this train of thought explains a lot.
And that might be why this pos is in the top 10 turds to short the past 8 years.
If the captain of the boat can’t read a compass
Most wouldn’t board the ship loaded with gold.

But it may require the IQ over 12.745

Why close shop when you can print shares and draw a salary? Jezzz
πŸ‘οΈ0
boston745 boston745 5 days ago
I dont really care about management. What i care about is the products getting to market. So either their partners need to step up or they need to close shop and auction the IP to companies that will bring products to market. Yes i do post the same thing...so do you if your honest. You just slightly reword what youre saying to push the same message while i use evidence to back my postion. If theres been a scam here, and I do agree there is one, it was to take Sintx public, use public funds to derisk/develop the IP, then sell the company cheap; this is what im fighting against, Sintx following Confor's path. Whether that was to try to take Sintx private as so many of you suggested or reverse merge (still on the table) with NP Aerospace, doesnt really matter. That is the scam I see and every social media account but me helps that plan along which is why Ive received death threats and my wife was harassed for over 100miles driving home about a month ago. Technically speaking the death threat was against my wife if i take the story about a killed husband literally.

Only large companies have the resources to move Sintx IP foward and Zimmer Biomet has been working with Sintx for going on 20 years...backed by evidence.

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439

Evidence suggesting Sintx and NP Aerospace are working on female specific armor
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175356997


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant

========================================

Theres two disinfo strawpuppet accounts mostly trolling me on Sintx and Tesla boards. Theres a reason for that, Means what i post is worth deeper examination. More on this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175304626

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 5 days ago
Absolutely fantastic! You've cracked the code, my friend. The logic is as airtight as a screen door on a submarine. Let's dissect this masterpiece of financial detective work, shall we?

Employee Share Plan Shenanigans:

Ah yes, the cunning conspiracy of the Reverse Split Rat Pack! Anson and his hedge fund henchmen, cackling in their lairs, must have cackled with glee as they orchestrated this elaborate scheme to... well, to what exactly? Deny hard-working employees some cheap shares? Is that the villainous masterplan here? Perhaps they're all secretly shorting the stock with nothing but whispers and dreams?

Goldmine Galore (Except for the pesky details):

Sintx, the sleeping giant of biomaterials! Competition? Who needs it when you have a secret sauce of "superiority at this time" and a licensing model that turns rivals into unwitting cash cows! Just picture it: millions of condoms shimmering with the revolutionary power of silicon nitride, a technological marvel for... well, let's just say "leak prevention."

Research Royale: The Paper Chase:

Hold onto your lab coats, folks! That research paper? It's practically a coronation decree for silicon nitride! Titanium, the current king of biomaterials, better pack its bags because Sintx is coming for its crown... with a PowerPoint presentation and some very convincing bullet points!

The Zimmer-Morgan-Solventum-NP-Cardinal Health Cinematic Universe:

Now this is where things get truly Ocean's Eleven. We've got a cast of characters worthy of their own action franchise! Morgan Ceramics, the ironclad supplier of... well, who knows, but it sounds impressive! Zimmer Biomet, the long-lost friend hiding "behind the curtain" (probably just waiting for the perfect dramatic reveal). And Cardinal Health, because hey, why not throw PPE into the mix? This is a superhero team-up for the ages, destined to conquer every medical market imaginable!

The Grand Market Menagerie:

Finally, the piΓ¨ce de rΓ©sistance! A market size bonanza so vast, it makes Jeff Bezos look like a lemonade stand operator. Let's just add all those billions together – orthopaedics, condoms, catheters (because apparently, variety is the spice of life in the medical device world)! Who cares about pesky details like profitability or actual product development? This is pure, unadulterated market size MADNESS!

The Verdict:

This, my friend, is a masterclass in investment research, where optimism meets speculation in a glorious tango. Sintx may not be the next Apple, but hey, it could be the next... well, who knows? But with this kind of enthusiasm, who needs facts anyway? Let's just grab our metaphorical shovels and start digging for that goldmine!
πŸ‘οΈ0
jimr1717 jimr1717 5 days ago
Incorrect Again! A basic roadmap laid out of Zimmer's intentions for Sintx was and is to sell shares, reverse split the stock and sell more shares.
One with an IQ over 9.745 can see this.
πŸ‘οΈ0
jimr1717 jimr1717 5 days ago
~Post~Of~Week~
πŸ‘οΈ0
joev2 joev2 5 days ago
You bring up the same stuff over and over again. Here's the scam: the investor was never part of the deal. He was only used to raise funds but was never to be part of the benefits. So, if indeed all the connections are there (assuming they're exactly collaborating as you envision) it doesn't matter to the investor. He was just a pawn. Personally speaking, whether or not Sint's material gets out there and benefits mankind (all well and good), I will ALWAYS see it as the retail investor being screwed, while the perpetrators got off scot free and even prospered. Sonny was and is a disgrace to EVERY individual that trusted him. I can probably say the same about Eric and Zimmer or whomever else that played the investor.

The potential of the product was never the problem; the people running the show always was and is. Who they are and how they did it and are doing it, doesn't matter in a sense. Sonny still collected, Anson still collected, Maxim still collected and the believers got dumped on. Plain and simple. I've called this stock out often because it's been quite evident to most, what's been going on. Just because some took a while to see it and others may never have, doesn't make the company any less than what it always was and still is. Refer back to my second sentence....

Again, the scam is how they played retail. So, no need to ask me if this is true or that is true and if I agree with this or that, or accusing me of not addressing something, or being part of some stupid conspiracy. I don/t care. As a retail investor, I would be furious with management and the SEC which allows all this crap.
πŸ‘οΈ0
boston745 boston745 5 days ago
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439

Evidence suggesting Sintx and NP Aerospace are working on female specific armor
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175356997


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
jimr1717 jimr1717 5 days ago
Perhaps Sintx could come up with a coating for tin foil hats for EMI resistants like their condom line.
πŸ‘οΈ0
jimr1717 jimr1717 6 days ago
Is your break even price $79,800 yet?


https://companiesmarketcap.com/sintx-technologies/stock-splits/
πŸ‘οΈ0
jimr1717 jimr1717 6 days ago
Chart forming the avalanche pattern. 5th Straight year.
πŸ‘οΈ0
jimr1717 jimr1717 6 days ago
The Boston789 sale on shares continues . No one beats Boston789’s discounts, No one.
πŸ‘οΈ0
boston745 boston745 6 days ago
Medtronic Completes Acquisition of Spinal Dynamics

The acquisition, valued at $269.5 million, will be structured as a stock merger, and will involve cash and stock.
In May, Spinal Dynamics began U.S. human clinical evaluation of the Bryan Cervical Disc System, an implanted prosthesis designed to replace
and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs.
Clinical evaluations of the device are being performed under an Investigational Device Exemption granted by the U.S. Food and Drug
Administration. The Bryan disc received CE Mark approval in Europe in September 2000 and has been distributed in more than 20 countries
outside the United States by Medtronic under a February 2001 agreement between SDC and Medtronic Sofamor Danek. To date, more than
1,000 patients have received the Bryan device, the first commercialized product of its kind.
SDC was founded in 1993 and has approximately 50 employees, and will become a unit of the Medtronic Sofamor Danek organization.
Medtronic invested $30m into Spinal Dynamics in Feb 2001 with Medtronic selling Bryan Cervical discs outside the US. There is no reason Zimmer Biomet, or some other partner of Sintx, couldnt do the same thing in regards to Sintx to distribute spinal products in the US and Europe utilizing Si3n4. Meanwhile that company could initiate various clinical trials for Arthoplasty products, dental, etc... Same thing could occur with say Cardinal Health using Sintx antipathogenic powder for PPE products. With the Trump administration removing lots of regulation beginning next year, major medical companies may find it easier to get products through the FDA...thats significantly helpful for Sintx and its partners moving forward.

You can listen to the naysayers here, including those manipulating the stock, or you can analyze the evidence thats not easily manipulated. That said im not sure management is trustworthy to be the stewards of Sintx IP in regards to bringing products to market. Sonny has done an excellent job creating value through the development of Sintx IP but didnt really try to bring products to market. We shall see if Olson is actually going to oversee products going to market with Sintx partners or not.

If you wonder why i bring up Spinal Dynamics, its to show that a company like Sintx can be acquired for hundreds of millions while its products are still pending trials. This was true for Implex as well, but Spinal Dynamics had zero FDA cleared products when Medtronics paid 270m for it; Spinal Dynamics only had 1 major product, a new type of cervical disc for spinal implants. Meanwhile Sintx already has clearance for its spinal iP utilizing dense Si3N4 with PEEK/Si3N4 forthcoming.

http://cdn.lso-inc.com/acquired/medtronic_spinaldynamics.pdf

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
boston745 boston745 6 days ago
Since you brought it up. The logic is simple. The Employee Share Plan had passed every time before last year. Why did it pass every time before then and why did it fail last year? What was different? One thing that was different was it was followed by a significant 200:1 RS. It that RS was already planned for, they had to vote down the plan so we could revote on it this year post RS. IE create the problem, control the reaction, implement the pre-planned solution. Another way of saying this is Anson and its co-conspiratorial hedge funds naked short the crap out of the Sintx offering while Sonny kept raising funds at lower prices creating the need for a RS as the market was flooded with shares.
Of course, if the employee plan fails, that just might mean a reverse split is coming


Look at all these juicy market sizes! Orthopaedic, PPE, catheters, condoms (because apparently everything is connected!), the possibilities are endless! Just add all these numbers together and voila, Sintx is sitting on a goldmine (ignoring pesky details like competition, profitability, and actual product development).
Yep, Sintx is sitting on a gold mine! Ive been saying this for years. Nevermind competition? There is no material out there thats superior, at this time, and Sintx model is to supply its "competitors". As ive shown before, a mere 5% market penetration at 5% licensing fee and Sintx would be looking at revenue of $800m a year across all those industries. All that needs to happen to kick this off is just of its significant partners stepping onto the stage instead of hiding behind the curtain. Obviously it will not happen overnight but it can accelerate quickly. Implex was in the 15-30m revenue range before merger with Zimmer. TM based revenue doubled in 2004 and was forecasted to exceed $100m in 2005. TM cant even touch all the markets Si3N4 can be used in.

=======================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
PioneerPhoenix73 PioneerPhoenix73 6 days ago
Oh boy, buckle up for this wild ride through Sintx-land!

Employee Share Plan Drama: A Play in One Act

Ah yes, the annual meeting filing! The suspense is killing us all...will those greedy employees finally get a slice of the non-existent pie? Don't worry, a reverse split is definitely coming next year, 2026 specifically (because apparently the stock market operates on a psychic calendar). Of course, if the employee plan fails, that just might mean a reverse split is coming – you know, because logic and dilution have nothing to do with it. But hey, at least management gets rewarded for...well, managing to keep the stock price stubbornly low!

Lind Partners Enters the Fray: The Shortening Savior (or Saboteur?)

Oh no, not Lind Partners! Those pesky hedge funds, always trying to distort reality with their pesky shorting tactics. But wait, didn't they also participate in pump schemes through Sabby Fund? Maybe they're just playing both sides for maximum chaos! Let's just throw some red herrings at the problem and see what sticks, shall we?

Connecting the Dots: A Conspiracy Web Worthy of a Thriller

Now this is where things get really interesting. Forget partnerships, let's talk secret alliances! Sintx is clearly in cahoots with Morgan Ceramics (aerospace!), Zimmer Biomet (arthroplasty – whatever that is!), and a whole host of other companies (because apparently diversification is for suckers!). And don't even get us started on NP Aerospace – are they making armor plates or something? This is bigger than Sintx, folks, it's a global medical-industrial-military complex orchestrated by...well, whoever you want it to be!

Market Mania: Numbers Don't Lie (Except When They Do)

Look at all these juicy market sizes! Orthopaedic, PPE, catheters, condoms (because apparently everything is connected!), the possibilities are endless! Just add all these numbers together and voila, Sintx is sitting on a goldmine (ignoring pesky details like competition, profitability, and actual product development).

In Conclusion: A Conspiracy (Theory) for the Ages

This is a masterclass in taking publicly available information and weaving a narrative that would make even the most seasoned conspiracy theorist blush. Remember, folks, correlation doesn't equal causation, and sometimes a cigar is just a cigar. But hey, if wild speculation and baseless connections are your thing, then this theory is a winner!
πŸ‘οΈ0
joev2 joev2 6 days ago
A simple test: let's see if this annual is the usual monologue (by whomever) or if the company is willing to at least show, they're trying to include and value an investor base by opening up the forum.
πŸ‘οΈ0
jimr1717 jimr1717 7 days ago
It would appear that shorting garbage like this has been fruitful.
At the same time it would appear that going long could bankrupt some.

This is a fake it, fake it again and if that fails reverse split it and fake it again.

But there are a few out there just like it.

I shorted this two reverse splits ago and it’s getting ready for its third.
https://investorshub.advfn.com/LogicMark-Inc-LGMK-27038
πŸ‘οΈ0
boston745 boston745 7 days ago
About time for the annual meeting filing. Be curious what will be on it? Should include a new vote on employee share plan since last years plan was voted down conveniently before a massive RS.
They just filed the annual meeting and it includes the new employee share plan expansion of shares. What direction that goes will give us an idea if there will be a RS next year into 2026 as some accounts like to invoke. If it fails theres a high chance of a RS. If it passes, which I expect, then RS is unlikely. I do not like how this is going down but you'll hear no argument from me that management & its employees deserves shares for the value they have created; even though that value is not currently reflected by the stock price. The sheer expansion of scope of IP is grounds enough in my opinion. Looks like the employee plan will give employees up to 20% of current outstanding shares when factoring in these new ones increasing OS to 1.6m if fully distributed because of a change in control.

Second filing today was Lind Partners indicating that they have 35,750 series E & 35,750 Series F warrants. The exercise price of those warrants should be 50 dollars. The Series F warrants expire August 2025. If they exercised those fully thats $3.6m unless they do some sort of cashless exercise.
The Class E and Class F Warrants were immediately exercisable at a price of $50.00 per share.


Lind is part of Ansons family of hedge funds that have been shorting and distorting on and off here since 2015 and played the pump in 2020 via Sabby fund. Here is the list of funds with all the funds in red being funds that have participated in Sintx offerings through the years.

Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.

List of potential investors the Plaintiff was referencing. All the funds that seem to be connected are in red.

List named the following:
Anson Funds Management LP and its affiliates
Ayrton Capital, Altos Opportunity Fund and their
affiliates
Crede Capital Group, Acquitas Capital and its affiliates
CVI Investment, Heights Management, SIG and their
affiliates
Connective Capital and its affiliates
Empery Asset Management and its affiliates
Intracoastal Capital LP and its affiliates
Hudson Bay Capital Management and its affiliates
Ionic Venture LLC and its affiliates
Lind Partners and its affiliates
Li Capital Global Opportunities Master Fund and their
affiliates
Sabby Management LLC and its affiliates


Quote Sources 2&3
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224044728/form10-q.htm pg 9
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
πŸ‘οΈ0
jimr1717 jimr1717 7 days ago
Today’s 2% discount wouldn’t be worth the trip to the store. May have to wait until next week for the $1 buck range like shopping at the dollar store.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock